Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 4,263 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) COO Cortney Caudill sold 4,263 shares of the business’s stock in a transaction that occurred on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the transaction, the chief operating officer directly owned 12,737 shares of the company’s stock, valued at $830,325.03. This trade represents a 25.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Halozyme Therapeutics Stock Up 3.4%

NASDAQ HALO traded up $2.24 during midday trading on Friday, hitting $67.35. 3,246,098 shares of the company traded hands, compared to its average volume of 2,070,158. Halozyme Therapeutics, Inc. has a 52 week low of $46.26 and a 52 week high of $79.50. The company’s 50-day simple moving average is $67.07 and its 200-day simple moving average is $64.82. The company has a market cap of $7.92 billion, a PE ratio of 14.18, a price-to-earnings-growth ratio of 0.36 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. During the same period in the prior year, the business posted $1.27 EPS. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HALO. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a report on Tuesday, October 14th. Leerink Partnrs raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Finally, Citizens Jmp increased their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $75.10.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently added to or reduced their stakes in HALO. Root Financial Partners LLC purchased a new position in shares of Halozyme Therapeutics in the third quarter worth about $25,000. Larson Financial Group LLC increased its holdings in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Richardson Financial Services Inc. increased its holdings in Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 198 shares during the period. Wealth Preservation Advisors LLC acquired a new position in Halozyme Therapeutics in the 1st quarter worth approximately $32,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $32,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.